|
1）Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253: 905-9
|
|
|
|
2）Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994; 78: 35-43
|
|
|
|
|
|
3）Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926-45
|
|
|
|
|
|
4）Brattström C, Säwe J, Jansson B, et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit. 2000; 22: 537-44
|
|
|
|
|
|
5）Klumpen HJ, Beijnen JH, Gurney H, et al. Inhibitors of mTOR. Oncologist. 2010; 15: 1262-9
|
|
|
|
|
|
6）Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012; 30: 4017-25
|
|
|
|
|
|
7）Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit. 2001; 23: 559-86
|
|
|
|
|
|
8）Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res. 2006; 12: 5755-63
|
|
|
|
|
|
9）Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006; 112: 184-98
|
|
|
|
|
|
10）Schoeppler KE, Aquilante CL, Kiser TH, et al. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014; 28: 590-7
|
|
|
|
|
|
11）MacPhee IA. Pharmacogenetic biomarkers: cytochrome P450 3A5. Clin Chim Acta. 2012; 413: 1312-7
|
|
|
|
|
|
12）Anglicheau D, Legendre C, Thervet E. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc. 2007; 39: 2142-4
|
|
|
|
|
|
13）Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005; 5: 595-603
|
|
|
|
|
|
14）Kim SG, Buel GR, Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells. 2013; 35: 463-73
|
|
|
|
|
|
15）Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149: 274-93
|
|
|
|
|
|
16）Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle. 2011; 10: 2305-16
|
|
|
|
|
|
17）Thoreen CC, Chantranupong L, Fau - Keys HR, et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012; 485: 109-13
|
|
|
|
|
|
18）Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-75
|
|
|
|
|
|
19）Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014; 14: 356-66
|
|
|
|
|
|
20）Liu M, Zhang W Fau - Gu M, Gu M Fau - Yin C, et al. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc. 2007; 39: 1410-5
|
|
|
|
|
|
21）Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transplant Immunol. 2014; 31: 22-32
|
|
|
|
|
|
22）Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. American J Transplant. 2013; 13: 1734-45
|
|
|
|
|
|
23）De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012; 12: 3008-20
|
|
|
|
|
|
24）Elsharkawi M Fau - Staib L, Staib L Fau - Henne-Bruns D, Henne-Bruns D Fau - Mayer J, et al. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005; 79: 851-9
|
|
|
|
|
|
25）Sato E, Hashi S, Taniguchi R, et al. Effectiveness of everolimus in combination with cyclosporine as treatment for chronic rejection in a pediatric patient undergoing liver transplantation. Jp J Ther Drug Monitor. 2014; 31: 1-5
|
|
|
|
|
|
26）Shinke H, Hashi S, Kinoshita R, et al. Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. Biol Pharm Bull. 2013; 36: 1221-5
|
|
|
|
|
27）Chen F, Omasa M, Kondo N, et al. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. The Ann Thorac Surg. 2009; 87: e6-7
|
|
|
|
|
|
28）Taveira-DaSilva AM, Moss J. Management of lymphangioleiomyomatosis. F1000Prime Rep. 2014; 6: 116
|
|
|
|
|
|
29）Yu L, McPhee CK, Zheng L, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010; 465: 942-6
|
|
|
|
|
|
30）Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015; 125: 25-32
|
|
|
|
|
|
31）Nakagawa S, Nishihara K, Inui K, et al. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol. 2012; 696: 143-54
|
|
|
|
|
|
32）Mathis AS, Egloff G, Ghin HL. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant. 2014; 4: 57-80
|
|
|
|
|
|
33）Pascual J. Everolimus in clinical practice--renal transplantation. Nephrol Dial Transplant. 2006; 21 Suppl 3: iii18-23
|
|
|
|
|